Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FBLN3 shRNA (lentiviral) is a gene-silencing tool designed to knock down the expression of fibulin-3 (FBLN3), an extracellular matrix glycoprotein. In the context of bladder cancer research, FBLN3 has been identified as a pro-invasive factor that is highly expressed in muscle-invasive transitional cell carcinoma (TCC) compared to non-muscle invasive stages. By utilizing a lentiviral vector to deliver short hairpin RNA (shRNA) targeting the FBLN3 transcript, researchers can achieve stable suppression of the protein. This knockdown has been shown to inhibit the migration and invasion of bladder cancer cell lines (such as T24 and UMUC-13) without affecting cell viability or growth rates, suggesting that FBLN3 is a potential therapeutic target for preventing cancer progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FBLN3 shRNA (lentiviral).